Otologic Pharmaceutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Otologic Pharmaceutics is a pioneering biotech firm targeting the vast, underserved market of sensorineural hearing loss. The company has two core platforms: a Phase II-ready, oral small molecule combination therapy (NHPN-1010) for conditions like tinnitus and acute hearing loss, and a preclinical siRNA-based regenerative program (Autigen siHES1) aimed at regrowing sensory hair cells. While still pre-revenue, the company has secured non-dilutive funding from the Department of Defense and is actively seeking partnerships to advance its pipeline.

OtologySensorineural Hearing LossTinnitus

Technology Platform

Dual-platform approach: 1) AUDITUS - an orally bioavailable small molecule combination therapy platform targeting neuroprotection and halting post-injury degeneration. 2) Autigen - an siRNA-based regenerative medicine platform designed to knock down HES1 to promote trans-differentiation of cochlear supporting cells into new sensory hair cells.

Opportunities

The company operates in a massive, untreated market with no FDA-approved pharmacotherapies for sensorineural hearing loss, offering a first-mover advantage for a successful drug.

Its dual-platform strategy allows it to address both symptomatic relief and potential curative regeneration, appealing to different partner and investor theses.

Securing a Department of Defense grant validates its technology and provides non-dilutive funding for high-risk research.

Risk Factors

High clinical risk as both platforms target complex, poorly understood biology with no established regulatory pathway for approval.

As a pre-revenue, private company, it faces significant financing risk and depends on raising capital or securing partnerships to advance its pipeline.

Competition is increasing as large pharma and other biotefts begin to invest in hearing loss therapeutics.

Competitive Landscape

The competitive landscape for disease-modifying hearing loss drugs is nascent but growing. Companies like Frequency Therapeutics (FX-322, now discontinued), Decibel Therapeutics (DB-020, DB-ATO), and Pipeline Therapeutics are developing various approaches. OPI's oral small molecule and siRNA regenerative approaches are distinct, but it will face increasing competition for funding, partnerships, and patient recruitment as the field matures.

More companies in Small Molecule Drugs →More companies in United States →